Advertisement
USFDA completes inspection of Cadila's Changodar plant
Drug firm Cadila Healthcare today said the USFDA has completed inspection of its manufacturing plant at Changodar with "no observation".
)
New Delhi: Drug firm Cadila Healthcare today said the USFDA has completed inspection of its manufacturing plant at Changodar with "no observation".
The United States Food and Drug Administration (USFDA) inspected the company's topical manufacturing facility at Changodar from April 3-7, 2017, Cadila Healthcare said in a BSE filing.
"At the end of the inspection, no observation (483) is issued," it added.
The company has filed 17 products with the FDA from this facility, Cadila Healthcare said.
Cadila Healthcare stock today closed 1.51 percent up at Rs 454.85 per scrip on BSE.
Stay informed on all the latest news, real-time breaking news updates, and follow all the important headlines in india news and world News on Zee News.
